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FIGURE 1 Survival Analysis of Death and HF Hospitalization-Free Survival in Patients
With Abnormal GLS Versus Normal GLS
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1557determined whether the accelerated collagen depo-
sition in the hypertensive heart is the result of
enhanced cardiomyocyte injury, increased oxidative
or nitrosative stress, a direct activation of cardiac
fibroblasts that may be predisposed to secrete
collagen due to the presence of hypertension, or a
combination thereof.Ev
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This Kaplan-Meier analysis aims to supply information regarding the event-free (hospi-
talization due to heart failure [HF]) survival of patients who have a normal left ven-
tricular ejection fraction (LVEF) and a normal GLS versus patients with an abnormal GLS. A
significant (log-rank ¼ 0.039) beneficial outcome regarding event-free survival is
observed in patients with a normal GLS. This finding suggests that in patients with a
normal LVEF, additional parameters (such as GLS) can provide additional insight in the
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With Recovered
Ejection FractionRecently, the term heart failure (HF) with recovered
ejection fraction (HFrecovEF) was introduced for pa-
tients with a normalization of the left ventricular
ejection fraction (LVEF) (1). The question remains
whether this means true recovery of systolic left
ventricular function or simply normalization of LVEF
as many patients show remaining abnormalities in
biomarker profiles and high hospitalization rate (1).Therefore, this research aims to assess the additional
value of global longitudinal strain (GLS) in patients
with HFrecovEF as physicians are left with un-
certainties regarding the therapeutic approach (e.g.,
halt or continue HF medication).
Patients were identified via the electronic hospital
health record system (EHR) based on the docu-
mented, routine LVEF measurement. In total, 212
patients met the inclusion criteria of an initial
LVEF <35% with improvement to $55%, and had a
complete follow-up. Patient characteristics were
collected from the EHR. The reason for developing HF
was rated according to the current ESC guidelines (2).
GLS was measured on routine echocardiographic im-
ages at the point of time that LVEF was normalized
using automated software (AutoLV module; part of
the TomTec-Arena 2.20.10; TomTec Imaging Systems,
Unterschleissheim, Germany). GLS was considered
normal if #21.5% and abnormal if >21.5% (3). The
primary endpoint was death or hospitalization due to
HF during a follow-up of 56  21 months (range 12 to
90 months) analyzed from normalization of LVEF
onwards.
The reason for HF in the HFrecovEF patients was
classified as: nonischemic (n ¼ 41), due to arrhyth-
mias (n ¼ 70), abnormal loading conditions (n ¼ 34),
and “other” (e.g., Takotsubo) (n ¼ 38). Patients with
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1558an ischemic cause (n ¼ 29) showed similar survival
and combined primary endpoint results as compared
with patients with a nonischemic etiology (n ¼ 183)
(p ¼ 0.91 and p ¼ 0.92, respectively). The duration
between onset of symptoms and initial echocardio-
gram was overall 10  7 (1 to 18) weeks, between
initial echocardiogram and follow-up echo was 16  8
(5 to 23) months. Overall, image quality was rated as
good (91%), moderate in 8%, and poor in 1% (p ¼ 0.26
between GLS groups).
Seventy-nine percent (n ¼ 168) of patients still
had an abnormal GLS despite normalization of LVEF.
No significant differences regarding symptoms,
medication, physical findings, further echocardio-
graphic measurements (e.g., mitral annular plane
systolic excursion, diastolic function) or underlying
etiologies of HF were detected comparing patients
with normal and abnormal GLS during follow-up.
Also, no significant differences regarding in-
terventions, operations, or new diagnoses were
observed between GLS groups. The vast majority of
patients (96%) showed a normal diastolic function at
the time of normalization of LVEF with no signifi-
cant difference between patients with normal/
abnormal GLS (p ¼ 0.11). Importantly, an abnormal
GLS was associated with a significantly worse
outcome of all-cause death and hospitalization due
to HF (Figure 1) compared with patients having a
normal GLS. There were 22 deaths in the group with
abnormal GLS and only 1 in the other group
(p ¼ 0.05).
Thus, HFrecovEF is purely defined on improve-
ment/normalization of LVEF. Still, normalization of
geometry and/or LVEF does not necessarily mean
full myocardial recovery (4). This difference is
clinically important as decisions are taken based on
dimensions and function rather than on tissue
characteristics. Therefore, the mere depiction of
LVEF, that is, volumetric changes, does not seem to
be a sufficiently comprehensive marker of systolic
function. GLS seems to provide additional charac-
terization of systolic function as a significantly
better death and HF hospitalization-free survival
was seen in patients with normal GLS. These find-
ings may have 2 direct implications for physicians
caring for patients with HFrecovEF: 1) because sys-
tolic function remains altered in most patients,
medication should not be ceased in patients with
HFrecovEF; and 2) because many physicians rely
on the measurement of LVEF, it calls for imple-
mentation of modern imaging tools (e.g., GLS or
stress echocardiography).
In conclusion, the majority of patients with HFre-
covEF still have an abnormal systolic function, asmeasured by GLS. Patients with an abnormal GLS,
despite normalization of LVEF, showed a significantly
worse outcome. Further studies should evaluate
therapeutic consequences.Jort Merken, MD
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Cardiol 2000;35:569–82.Infective Endocarditis
and Valve-Pathogen
PredilectionWe read with great interest the excellent work of
Zegri-Reiriz et al. (1), who have provided critical
insight into the syndrome of infective endocarditis
